Search research articles
Contact Us
Filters
Showing results (181-190 of 484) with videos related to
Page
of 49
Sort By:
Clinical and Experimental Rheumatology
|
August 4, 2025
Impact of immunosuppression on development and outcome of systemic sclerosis-associated pulmonary arterial hypertension
Stefano Rodolfi, Cheryl Chun Man Ng, Ana Maria Ruiz Bejerano, et al.
The European Respiratory Journal
|
August 29, 2024
Definition, classification and diagnosis of pulmonary hypertension
Gabor Kovacs, Sonja Bartolome, Christopher P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
September 19, 2022
Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis
Svetlana I Nihtyanova, Benjamin E Schreiber, Voon H Ong, et al.
Annals of the Rheumatic Diseases
|
January 17, 2012
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
Christopher P Denton, Thomas Krieg, Loic Guillevin, et al.
Arthritis and Rheumatism
|
April 1, 2006
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts
Yunliang Chen, Xu Shi-wen, Mark Eastwood, et al.
The Journal of Rheumatology
|
April 3, 2008
Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis
Maria Teresa Carulli, Paolo Spagnolo, Carmen Fonseca, et al.
Clinical and Experimental Rheumatology
|
April 6, 2021
Autologous lipotransfer can improve the outcomes of localised scleroderma
Benjamin J Langridge, Faith H K Jeon, Aurora Almadori, et al.
Annals of the Rheumatic Diseases
|
September 23, 2020
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Yannick Allanore, Peter Wung, Christina Soubrane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study
Yannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Scientific Reports
|
July 2, 2022
Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes
Kristina E N Clark, Corrado Campochiaro, Lauren V Host, et al.
Page
of 49
Search research articles
Search
Showing results (181-190 of 484) with videos related to
Sort By:
Page
of 49
Clinical and Experimental Rheumatology
|
August 4, 2025
Impact of immunosuppression on development and outcome of systemic sclerosis-associated pulmonary arterial hypertension
Stefano Rodolfi, Cheryl Chun Man Ng, Ana Maria Ruiz Bejerano, et al.
The European Respiratory Journal
|
August 29, 2024
Definition, classification and diagnosis of pulmonary hypertension
Gabor Kovacs, Sonja Bartolome, Christopher P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
September 19, 2022
Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis
Svetlana I Nihtyanova, Benjamin E Schreiber, Voon H Ong, et al.
Annals of the Rheumatic Diseases
|
January 17, 2012
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
Christopher P Denton, Thomas Krieg, Loic Guillevin, et al.
Arthritis and Rheumatism
|
April 1, 2006
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts
Yunliang Chen, Xu Shi-wen, Mark Eastwood, et al.
The Journal of Rheumatology
|
April 3, 2008
Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis
Maria Teresa Carulli, Paolo Spagnolo, Carmen Fonseca, et al.
Clinical and Experimental Rheumatology
|
April 6, 2021
Autologous lipotransfer can improve the outcomes of localised scleroderma
Benjamin J Langridge, Faith H K Jeon, Aurora Almadori, et al.
Annals of the Rheumatic Diseases
|
September 23, 2020
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Yannick Allanore, Peter Wung, Christina Soubrane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study
Yannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Scientific Reports
|
July 2, 2022
Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes
Kristina E N Clark, Corrado Campochiaro, Lauren V Host, et al.
Page
of 49